Pharmacogenetic variants and risk of remdesivir‐associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID‐19

• Main Authors: Sony Tuteja (Author), Zhihong Yu (Author), Otis Wilson (Author), Hua‐Chang Chen (Author), Frank Wendt (Author), Cecilia P. Chung (Author), Shailja C. Shah (Author), Christine M. Hunt (Author), Ayako Suzuki (Author), Catherine Chanfreau (Author), Bryan R. Gorman (Author), Jacob Joseph (Author), Shiuh‐Wen Luoh (Author), Valerio Napolioni (Author), Cassianne Robinson‐Cohen (Author), Ran Tao (Author), Jin Zhou (Author), Kyong‐Mi Chang (Author), Adriana M. Hung (Author), the VA Million Veteran Program COVID‐19 Science Initiative (Author)
• Format: Book
• Published: Wiley, 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Remdesivir is the first US Food and Drug Administration (FDA)‐approved drug for the treatment of coronavirus disease 2019 (COVID‐19). We conducted a retrospective pharmacogenetic study to examine remdesivir‐associated liver enzyme elevation among Million Veteran Program participants hospita...